Valuation: CSL Limited

Capitalization 75.66B 65.29B 61.36B 55.64B 103B 6,501B 116B 716B 279B 2,978B 284B 278B 10,903B P/E ratio 2025 *
25.6x
P/E ratio 2026 * 22.3x
Enterprise value 85.11B 73.44B 69.03B 62.6B 115B 7,313B 130B 805B 314B 3,350B 319B 313B 12,265B EV / Sales 2025 *
5.42x
EV / Sales 2026 * 5.02x
Free-Float
99.9%
Yield 2025 *
1.87%
Yield 2026 * 2.07%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.30%
1 week-1.77%
Current month-2.91%
1 month-0.83%
3 months-3.26%
6 months-13.36%
Current year-14.83%
More quotes
1 week 237.66
Extreme 237.66
245.15
1 month 237.66
Extreme 237.66
251.08
Current year 228.61
Extreme 228.61
290.32
1 year 228.61
Extreme 228.61
313.55
3 years 228.61
Extreme 228.61
314.28
5 years 228.61
Extreme 228.61
320.42
10 years 85.4
Extreme 85.4
342.75
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 05/03/2023
Chief Tech/Sci/R&D Officer 63 30/09/2020
Chief Tech/Sci/R&D Officer 67 30/09/2018
Director TitleAgeSince
Director/Board Member 71 16/10/2018
Director/Board Member 69 13/08/2013
Director/Board Member 67 15/02/2016
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.48%-1.77%-16.96%-7.29% 75.29B
-0.39%+1.50%+37.72%+28.48% 53.15B
-0.92%-0.49%+17.48%+101.48% 35.91B
+0.30%-1.57%-43.44%-33.57% 19.14B
-0.50%+9.77%+109.66%+205.32% 16.98B
+5.19%+10.04%+53.02%+952.11% 15.1B
-0.04%-.--%+94.58%+133.27% 14.02B
+5.12%+3.56%+14.67%+3.89% 13.11B
-2.20%-12.17%-4.63%-32.48% 11.47B
+0.04%-0.72%-32.65%-24.15% 10.78B
Average +0.69%+0.34%+22.94%+132.71% 26.5B
Weighted average by Cap. +0.33%-0.24%+16.23%+87.23%
See all sector performances

Financials

2025 *2026 *
Net sales 15.7B 13.55B 12.73B 11.55B 21.29B 1,349B 24.03B 148B 57.87B 618B 58.91B 57.67B 2,262B 16.69B 14.41B 13.54B 12.28B 22.64B 1,434B 25.55B 158B 61.54B 657B 62.63B 61.31B 2,406B
Net income 2.98B 2.57B 2.41B 2.19B 4.04B 256B 4.56B 28.15B 10.97B 117B 11.17B 10.93B 429B 3.39B 2.93B 2.75B 2.5B 4.6B 292B 5.19B 32.1B 12.51B 134B 12.73B 12.47B 489B
Net Debt 9.45B 8.16B 7.67B 6.95B 12.82B 812B 14.47B 89.41B 34.85B 372B 35.47B 34.72B 1,362B 8.14B 7.03B 6.6B 5.99B 11.04B 700B 12.46B 77.01B 30.01B 320B 30.55B 29.9B 1,173B
More financial data * Estimated data
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
32,698
More about the company
Date Price Change Volume
17/06/25 238.75 $ -0.15% 228,675
16/06/25 239.10 $ +0.10% 386,113
13/06/25 238.86 $ -0.91% 723,664
12/06/25 241.05 $ +0.08% 622,476
11/06/25 240.85 $ -1.34% 501,001

Delayed Quote Australian S.E., June 17, 2025 at 01:38 am

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
156.25USD
Average target price
202.35USD
Spread / Average Target
+29.50%
Consensus

Quarterly revenue - Rate of surprise